Wedbush analyst Yun Zhong has maintained their bullish stance on MNKD stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yun Zhong has given his Buy rating due to a combination of factors related to MannKind’s strategic decisions and product potential. Despite the discontinuation of MNKD-101, the company is advancing with MNKD-102, which is expected to provide better pharmacokinetic exposure and could enter clinical trials by the second half of 2026. This strategic pivot reflects MannKind’s adaptability and focus on leveraging its pipeline for future growth.
Moreover, MannKind’s current commercial product portfolio, including Tyvaso DPI, Furoscix, and Afrezza, continues to show strong growth potential, which supports the company’s valuation. Additionally, the development of MNKD-201 for idiopathic pulmonary fibrosis presents a significant upside opportunity. These factors collectively underpin Yun Zhong’s confidence in MannKind’s future prospects, justifying the Buy rating with a price target adjustment from $11 to $10.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.